PHARMACOKINETICS AND IMMUNE RESPONSE STUDY WITH AN ANTI-CD3 MONOCLONAL ANTIBODY

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。针对T淋巴细胞CD3受体的单克隆抗体（抗CD3）已被证明是一种有效的免疫抑制剂，用于临床情况，如器官移植和糖尿病后的类固醇难治性同种异体移植排斥反应。同时，这些单克隆抗体的给药可能会因t细胞活化导致细胞因子释放综合征（CRS）而复杂化。本研究的目的是研究基因工程抗cd3 IgG单克隆抗体CNTO311对CRS的作用。良好的结果将为开发CNTO311用于临床提供依据。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Monoclonal antibodies directed against the CD3 receptor of T lymphocytes (anti-CD3) have been shown to be effective immunosuppressive agents for use in clinical situations such as steroid-refractory allograft rejection following organ transplantation and diabetes. At the same time, administration of these monoclonal antibodies may be complicated by T-cell activation resulting in cytokine release syndrome (CRS). The purpose of this study is to investigate CNTO311, a genetically engineered anti-CD3 IgG monoclonal antibody, with regard to CRS. Favorable results will provide justification to develop CNTO311 for use in the clinical situations.